United States Patent 8,895,756: Bendamustine Hydrochloride and Mannitol Vial Claims

U.S. Patent No. 8,895,756 protects a narrowly defined bendamustine hydrochloride presentation rather than bendamustine as an active pharmaceutical ingredient. The claims require a vial containing a reconstituted sterile aqueous solution, bendamustine hydrochloride, mannitol, a specified 15:25.5 weight ratio, and a concentration of 100 mg in 20 mL. Claim 4 independently specifies the commercially relevant 100 mg/170 mg/20 mL configuration.

The patent therefore targets the finished injectable presentation and its reconstituted composition. It does not, based on the supplied claims, cover every bendamustine formulation, every vial size, lyophilized bendamustine, concentrated bendamustine solutions, or formulations using a different excipient.

What does U.S. Patent 8,895,756 protect?

The patent protects a vial containing reconstituted bendamustine hydrochloride and mannitol in sterile water for injection. Its core limitations are:

Claim limitation	Claim 1	Claim 2	Claim 3	Claim 4
Vial	Yes	Yes	Yes	Yes
Reconstituted solution	Yes	Yes	Yes	Yes
Bendamustine hydrochloride	Yes	Yes	Yes	Yes
Mannitol	Yes	Yes	Yes	Yes
Sterile water for injection	Yes	Yes	Yes	Yes
Bendamustine:mannitol ratio of 15:25.5 by weight	Yes	Yes	Yes	Implicit through quantities
Bendamustine concentration of 100 mg/20 mL	Yes	Yes	Yes	Yes
25 mg bendamustine amount	No	Yes	No	No
100 mg bendamustine amount	No	No	Yes	Yes
170 mg mannitol amount	No	No	No	Yes

The claimed ratio simplifies mathematically to 10:17. The claim, however, recites 15:25.5. A formulation containing 100 mg of bendamustine hydrochloride and 170 mg of mannitol has the same ratio.

How should the independent claims be interpreted?

Claims 1 and 4 are the principal scope-defining provisions.

Claim 1

Claim 1 requires all of the following:

A vial.
A reconstituted solution.
Bendamustine hydrochloride in the solution.
Mannitol in the solution.
Sterile water for injection as the aqueous vehicle.
A bendamustine-to-mannitol weight ratio of 15:25.5.
Bendamustine hydrochloride at 100 mg per 20 mL.

The wording "100 mg per 20 mL" is a concentration limitation. On its face, it does not require the vial to contain exactly 100 mg total. A 20 mL vial containing 100 mg satisfies the limitation. A larger vial containing 200 mg in 40 mL could also meet the concentration limitation if the other elements are present, although claim construction would determine whether the claim’s vial-specific language imposes a narrower volume requirement.

Claim 4

Claim 4 is independently important because it recites fixed quantities:

100 mg bendamustine hydrochloride;
170 mg mannitol;
reconstitution in sterile water for injection;
a 20 mL vial.

Claim 4 avoids reliance on an inferred ratio or concentration. It is directed to the exact 100 mg presentation. A product that contains 100 mg of bendamustine hydrochloride and 170 mg of mannitol in a 20 mL vial would face the clearest literal-infringement risk if the product is reconstituted in sterile water for injection.

What formulations are protected by U.S. Patent 8,895,756?

The claims cover a specific reconstituted injectable formulation. They do not expressly require a particular pH, osmolality, preservative, buffer, storage temperature, container closure, manufacturing process, or administration method.

The protected formulation can be represented as follows:

Parameter	Claimed requirement
Active ingredient	Bendamustine hydrochloride
Excipient	Mannitol
Vehicle	Sterile water for injection
Ratio	15:25.5 bendamustine hydrochloride to mannitol by weight
Concentration	100 mg bendamustine hydrochloride per 20 mL
Exact 100 mg presentation	100 mg bendamustine hydrochloride and 170 mg mannitol in 20 mL
Dosage form	Reconstituted injectable solution in a vial

A lyophilized cake before reconstitution may not, by itself, satisfy the reconstituted-solution limitations. The analysis changes if the patent claims or specification treat the product as a kit, a vial containing powder plus diluent, or a product intended for reconstitution. The supplied claims are limited to the reconstituted state.

How broad are claims 2 and 3?

Claims 2 and 3 are dependent claims and add the total bendamustine amount.

Claim 2 covers the 25 mg presentation. Because claim 1 requires 100 mg per 20 mL, the natural corresponding configuration is 25 mg in 5 mL if the same concentration is maintained. The claim text supplied does not expressly require a 5 mL fill volume. It requires the claim 1 concentration and a 25 mg amount.

Claim 3 covers the 100 mg presentation. It is narrower than claim 1 because it requires a particular total amount, but it aligns with the concentration and the principal 20 mL presentation.

A product can infringe claim 1 without infringing claims 2 or 3 if it meets the claim 1 concentration and ratio but uses a different total bendamustine amount. Conversely, a product containing 100 mg may avoid infringement if it uses a different mannitol amount, a different diluent, or a different final concentration.

What is the infringement risk for competing bendamustine products?

The strongest literal-infringement scenario is a product with the following profile:

Product characteristic	Risk under the supplied claims
100 mg bendamustine hydrochloride	High if other limitations match
170 mg mannitol	High
Reconstituted in sterile water for injection	High
20 mL vial	High under claim 4
100 mg in a final 20 mL volume	High
Different mannitol amount	Potentially avoids literal infringement
Saline or another diluent instead of sterile water for injection	Potentially avoids literal infringement
Different bendamustine concentration	Potentially avoids claim 1
Different dosage form, such as a concentrate	Potentially avoids the supplied claims
No vial, such as a bulk container or prefilled syringe	Potentially avoids the vial limitation

The analysis must be performed on the accused product as sold and, where relevant, as reconstituted according to its labeling. A manufacturer cannot necessarily avoid risk by selling a powder if the product labeling directs reconstitution into the claimed composition and the relevant claim reaches the product in that state.

Can a generic avoid the patent by changing the mannitol ratio?

A noninfringing design could use a mannitol quantity materially different from the claimed ratio. For a 100 mg bendamustine presentation, the claimed mannitol amount is 170 mg. A formulation containing 100 mg bendamustine and 150 mg or 200 mg mannitol would not literally meet the 15:25.5 ratio or the 100 mg/170 mg limitation in claim 4.

The doctrine of equivalents could still be asserted, but equivalence would depend on the patent’s prosecution history, claim construction, technical effect of the ratio, and whether the proposed variation was surrendered during prosecution. A formulation change that eliminates a claimed excipient or materially changes the quantitative composition generally presents a stronger design-around position than a minor manufacturing variation.

Can a generic avoid the patent by using a different diluent?

The claims expressly recite sterile water for injection. A formulation reconstituted with another vehicle could avoid literal infringement of the supplied claims. That strategy carries regulatory and technical constraints because the diluent must be compatible with bendamustine hydrochloride, maintain stability, meet injectable-product requirements, and be reflected in the product’s labeling.

A generic product using normal saline, a buffered aqueous vehicle, or another approved diluent would require separate analysis under the patent’s specification and any unprovided claims. The supplied claims alone do not cover every aqueous diluent.

Does the patent cover Bendeka, Treanda, or another bendamustine product?

Claim analysis alone does not establish product coverage. Coverage depends on the formulation, dosage form, labeling, reconstitution instructions, and the patent listings associated with the relevant FDA application.

Bendamustine products have used different presentations, including lyophilized powders and ready-to-dilute solutions. A product marketed as a concentrate may present a different infringement profile from a vial that is reconstituted with sterile water for injection. The product’s commercial name is not determinative; the quantitative formulation and labeled preparation instructions control.

The FDA Orange Book should be reviewed for the relevant application number and listed patent use codes. The Orange Book identifies patents submitted by an NDA holder under Section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act, but it does not resolve infringement or validity questions. The FDA does not independently adjudicate whether the listed patent claims cover a particular generic product (FDA, 2024).

What patent claims are likely to matter beyond U.S. Patent 8,895,756?

A complete bendamustine patent landscape normally includes five patent categories:

Patent category	Relevance to a generic
Composition patents	Active ingredient, salt, polymorph, or chemical form
Formulation patents	Mannitol ratio, concentration, pH, stability, or lyophilization
Method-of-use patents	Treatment of lymphoma, leukemia, or other cancers
Manufacturing patents	Synthesis, purification, crystallization, or sterile filling
Device or packaging patents	Vial, closure, transfer system, or reconstitution configuration

U.S. Patent 8,895,756, based on the supplied claims, is a formulation and presentation patent. It does not claim a therapeutic method, manufacturing process, or delivery device.

What Paragraph IV risks exist?

A generic applicant filing an ANDA must address each patent listed for the reference product. For a listed formulation patent, the applicant may submit a Paragraph IV certification asserting that the patent is invalid, unenforceable, or will not be infringed. The NDA holder may then bring an infringement action under 21 U.S.C. § 271(e)(2).

For this patent, likely Paragraph IV theories would include:

noninfringement based on a different mannitol quantity;
noninfringement based on a different diluent;
noninfringement based on a different concentration or vial volume;
anticipation by an earlier bendamustine formulation;
obviousness based on known bendamustine formulations and conventional injectable excipients;
indefiniteness concerning concentration, reconstitution, or the meaning of the vial limitations;
lack of written description or enablement, depending on the full specification.

The quantitative limitations can strengthen validity against a broad prior-art challenge because the claim is narrow. They can also create design-around opportunities for a generic developer.

What patent litigation and settlement issues should be reviewed?

The supplied claim text does not establish litigation status, settlement terms, launch dates, or the current enforceability of U.S. Patent 8,895,756. Those issues must be determined from the USPTO patent record, FDA Orange Book, PACER or docket records, and any ANDA settlement filings.

Key litigation questions include:

Whether the patent was listed for a bendamustine NDA.
Whether an ANDA applicant filed a Paragraph IV certification.
Whether the patent holder brought a 30-month-stay litigation.
Whether a court construed the ratio, concentration, or vial limitations.
Whether the patent was challenged in an inter partes review.
Whether a settlement permitted a licensed or at-risk generic launch.
Whether the patent expired, was disclaimed, or remains enforceable.

A settlement may permit entry before the nominal patent expiration date, but the commercial entry date is controlled by the agreement and applicable regulatory exclusivity.

How strong is the patent estate represented by this patent?

The individual claim set is narrow but commercially targeted. Its strengths are:

exact identification of the finished presentation;
quantitative limitations that can be tested analytically;
independent claim 4 directed to the 100 mg/170 mg/20 mL configuration;
coverage of the reconstituted product rather than only an intermediate.

Its weaknesses or attack points are:

dependence on exact formulation parameters;
potential design-around through a different mannitol ratio;
potential design-around through a different diluent;
possible dispute over whether the accused product is a claimed "reconstituted solution";
possible prior-art challenges directed to known bendamustine-mannitol formulations;
limited reach to alternative concentrations and dosage forms.

The patent is therefore more useful as a product-specific barrier than as a platform patent covering the bendamustine market.

What is the commercial impact of U.S. Patent 8,895,756?

Commercial exposure depends on the revenue attributable to the exact protected presentation, not total bendamustine sales. The relevant product data are:

annual U.S. sales of the reference product;
share of sales from the 25 mg and 100 mg vials;
whether the product is reconstituted in sterile water for injection;
whether competing products use the same 15:25.5 ratio;
the number and timing of ANDA applicants;
remaining regulatory exclusivity;
settlement-controlled launch dates.

A generic that changes the formulation may avoid this patent while remaining clinically and commercially substitutable. The patent can therefore delay a direct copy without necessarily preventing all bendamustine competition.

Key Takeaways

U.S. Patent 8,895,756 is directed to a specific reconstituted bendamustine hydrochloride and mannitol vial.
The core ratio is 15:25.5 by weight, equivalent mathematically to 10:17.
Claim 4 specifically targets 100 mg bendamustine hydrochloride, 170 mg mannitol, and a 20 mL vial.
The claims require sterile water for injection and do not, from the supplied text, cover every diluent.
The patent does not broadly claim bendamustine, all bendamustine salts, all injectable formulations, or all cancer-treatment methods.
The most practical design-around routes are a different mannitol ratio, a different diluent, a different concentration, or a different dosage form.
Paragraph IV exposure depends on Orange Book listing, the ANDA formulation and labeling, and the patent’s current legal status.
Patent strength is commercially meaningful for an exact-copy product but narrower than a platform patent.

Frequently Asked Questions

Does 100 mg of bendamustine with 170 mg of mannitol satisfy the claimed ratio?

Yes. The ratio is 100:170, which reduces to 10:17 and is equivalent to 15:25.5.

Does a vial containing bendamustine powder infringe the supplied claims?

Not necessarily. The claims recite a reconstituted solution. A powder-only product requires analysis of the full patent, labeling, reconstitution instructions, and any additional claims.

Does the patent cover a 25 mg bendamustine vial?

Claim 2 expressly covers a 25 mg vial if all limitations of claim 1 are satisfied, including the claimed concentration, ratio, reconstituted state, and sterile water vehicle.

Can a manufacturer use 100 mg of bendamustine with 160 mg of mannitol?

That formulation would not literally meet the 100 mg/170 mg limitation of claim 4 or the 15:25.5 ratio, but doctrine-of-equivalents and the patent’s prosecution history would require separate analysis.

Is U.S. Patent 8,895,756 the only patent that can block a bendamustine generic?

No. Other formulation, method-of-use, manufacturing, packaging, regulatory-exclusivity, or separately listed patents may affect market entry.

References

Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. U.S. Department of Health and Human Services.
United States Patent and Trademark Office. (2014). U.S. Patent No. 8,895,756. U.S. Department of Commerce.
United States Code. (2023). 35 U.S.C. § 271(e)(2): Infringement actions based on drug applications.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cephalon	TREANDA	bendamustine hydrochloride	POWDER;INTRAVENOUS	022249-002	May 1, 2009	AP	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial			Y		⤷ Start Trial
Cephalon	TREANDA	bendamustine hydrochloride	POWDER;INTRAVENOUS	022249-001	Mar 20, 2008	AP	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	052877	⤷ Start Trial
Australia	2006204817	⤷ Start Trial
Brazil	PI0606332	⤷ Start Trial
Canada	2593582	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,895,756

Which drugs does patent 8,895,756 protect, and when does it expire?

Summary for Patent: 8,895,756